Pitavastatin sodium

Pitavastatin sodium is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated in abnormal circulating lipid concentration and hyperlipidemia. It is grouped under the following drug class(es): Cholesterol-reducing agents, Lipid-lowering agents and Statins. Its therapeutic use is listed as cardiovascular. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include 6-Heptenoic acid, 7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3, 5-dihydroxy-, sodium salt (1:1), (3R, 5S, 6E)- and Livalo. Its PubChem CID is 23696934.

CAS No 574705-92-3
Molecular Formula C25H23FNNaO4
Molecular Weight 443.4 g/mol
Synonyms sodium;(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate

Frequently Asked Questions